Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
6 min read
Chengdu Olymvax Biopharmaceuticals, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Chengdu Olymvax Biopharmaceuticals, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
ChemoCentryx, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of ChemoCentryx, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Checkpoint Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Checkpoint Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Celyad Oncology SA Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Celyad Oncology SA, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Imunon, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Imunon, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Centrose LLC Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Centrose LLC, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Certa Therapeutics Pty Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Certa Therapeutics Pty Ltd., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
ARIBIOLAB Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of ARIBIOLAB, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
GenPat77 Pharmacogenetics AG Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of GenPat77 Pharmacogenetics AG, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Celldex Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Celldex Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Cellectar Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cellectar Biosciences, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Cellatoz Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Cellatoz Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.